Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-24

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To investigate the biomarkers of MND/FTD spectrum disease
2. To explore the possible pathogenesis of MND/FTD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging

NCT06827678

Alzheimer Disease Positron Emission Tomography

RECRUITING

Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

NCT06092125

Alzheimer Disease Parkinson Disease Epilepsy +1 more

RECRUITING

Ruijin Neurobank of Alzheimer's Disease and Dementia

NCT05623124

Dementia

RECRUITING

Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia

NCT06534658

Alzheimer Disease Image

RECRUITING

Multi-center Imaging Genetics Studies in China

NCT02681822

Alzheimer Disease Schizophrenia Major Depressive Disorders

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Motor neuron disease (MND) is a group of disease characterized by motor neuron disorders and neurodegeneration. MND and frontotemporal dementia (FTD) were believed to comprise a neurodegenerative disease spectrum. The prognosis of the disease spectrum varies according to the type of disease, and the diagnosis of patients is often delayed due to insufficient diagnostic biomarkers. In recent years, the academic community has made significant progress in the study of biomarkers of the disease, but there is still a lack of specific biomarkers with strong diagnostic value. Besides, the low prevalence makes it difficult to carry out studies with large samples. The aim of this study was to explore diagnostic biomarkers of the disease spectrum by collecting variable samples from a large group of patients. The findings will both offer a better understanding of MND/FTD spectrum disease and also support the development of a model to study other rare diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis Frontotemporal Dementia Motor Neuron Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Inclusion Criteria:

1. Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020.

Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines
2. Informed consent signed

Exclusion Criteria

1. Patients who receive alternative diagnoses during the follow-up.
2. Patients who refuse to sign informed consent.

No interventions assigned to this group

Control

Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.

Exclusion criteria:

1. Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on.
2. Individuals who refuse to sign informed consent.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020.

Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines

Exclusion Criteria

* Patients who receive alternative diagnoses during the follow-up.
* Patients who refuse to sign informed consent.

Control group:

Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.

1. Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on.
2. Individuals who refuse to sign informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No